European Parliament ITRE committee adopts IMI2 regulation
15.04.14
IMI2 will take the collaborative vision of IMI even further in its service to patients and the public health agenda. IMI2 relied heavily on the World Health Organization’s Report on Priority Medicines for Europe and the World in determining its Strategic Research Agenda. The SRA, an essential element of the evolution from IMI to IMI2, was determined with input from more than 80 organisations, including regulators, patients, academia and learned societies. The first five big questions to be addressed by IMI2 include neuro-degeneration, metabolic disorders, immune-mediated diseases, infections and translational safety.
The IMI2 legal package will be released for legislative process in July. The results are anticipated to offer the necessary framework that will allow IMI to remain the largest public-private partnership (PPP) in biopharmaceutical research worldwide. The launch of IMI2 and first Calls for proposals are planned for 9 July.